MRNA (Moderna) Valuation — Probability-Weighted DCF After INTerpath-001, August 2026

Equity Research Note — Probability-Weighted DCF After the INTerpath-001 Readout

26 August 2026 | Prices as of 25 August 2026 close

1. Thesis in one paragraph

The INTerpath-001 Phase 3 result is a genuine scientific landmark: the first positive late-stage readout for any individualized neoantigen therapy. The equity is a different question. Moderna owns half of intismeran, not all of it, under a 50/50 worldwide cost and profit split with Merck. That single asset sits on top of a base business whose revenue fell 40% in 2025 to USD 1.944B and whose FY26 guidance implies a 19% gross margin, against USD 5.6B of operating cost. Net cash is only 8% of market capitalisation. At USD 158.83 the enterprise value is USD 57.7B, and reverse-solving that number requires intismeran to generate worldwide peak sales beyond melanoma of roughly USD 101B at a 50% probability of success. Keytruda peaks near USD 30B. The science is real; the price is not.

2. Verified position

Item	Value
Price (25 Aug 2026)	USD 158.83 (+14.36%)
Diluted shares (derived from Q2 loss / EPS)	397.0m
Market capitalisation	USD 63.1B
Cash and investments (30 Jun 2026)	USD 6.9B
less litigation settlement paid July 2026	-USD 0.95B
less credit facility drawn	-USD 0.60B
Net cash (8% of market cap)	USD 5.35B
Implied enterprise value	USD 57.7B
FY2025 revenue	USD 1.944B (down 40% YoY)
FY2026 revenue guidance	up to 10% growth (approx USD 2.1B)
FY2026 cost of sales / R&D / SG&A	USD 1.7B / 2.9B / 1.0B
Year-end 2026 cash guidance	USD 4.7-5.2B

The FY26 income statement in one line: approximately USD 2.1B of revenue against USD 5.6B of operating cost. Gross margin on guidance is 19%. Moderna is carrying stranded manufacturing capacity built for a pandemic that has ended.

3. WACC from first principles

Input	Value
Risk-free rate (US 10Y) — UNVERIFIED	4.75%
Equity risk premium (Damodaran mature market)	4.50%
Unlevered beta, Drugs (Biotechnology)	1.28
Debt / equity	0.95%
Levered beta (Hamada)	1.290
Cost of equity (CAPM)	10.55%
WACC	10.51%

A 5.50% risk-free rate produces a WACC of 11.25%. The rate error is asymmetric: it runs against the valuation, not for it.

4. Method note: two corrections made during the build

Both moved the answer materially and are disclosed because they should be auditable:

1. The first pass double-counted. An rNPV sum-of-the-parts valued the COVID franchise and mRESVIA as standalone assets while simultaneously netting their revenue inside the corporate burn line. Rebuilt as a single company-level cash flow stream, with intismeran entering as Moderna's 50% share of collaboration operating profit.
2. The first pass produced negative equity value in the bear case. That is not a real outcome for a company with net cash. Equity is an option, floored by wind-down value plus the sale value of the 50% intismeran stake. Operating expense was also made adaptive: Moderna removed approximately USD 2.2B of annual cost in 2025, so holding R&D flat at USD 2.9B through 2040 was not a scenario any management would run.

Owner FCF basis: depreciation and amortisation added back with capital expenditure modelled separately at USD 0.25B. Stock-based compensation is not added back.

5. Probability-weighted DCF

Assumption	Bear	Base	Bull
COVID franchise steady state	0.9	1.3	1.7
mFlusiva peak sales	0.7	1.8	3.0
Steady-state gross margin	55%	62%	68%
INT melanoma peak WW / PoS	3.0 / 75%	6.0 / 85%	9.0 / 92%
INT expansion peak WW / PoS	1.0 / 15%	8.0 / 35%	22.0 / 55%
Steady-state R&D plus SG&A	2.2	3.0	3.5
Enterprise value (USD B)	-11.2	1.9	29.9
NAV after option floor (USD B)	6.9	9.9	35.2
Per share (USD)	17.25	24.81	88.65

Base case annual cash flow path, USD billions:

Year	Revenue	Gross profit	INT share	Opex	FCF
2026	1.65	0.31	0.00	3.90	-2.89
2028	2.46	1.17	0.21	3.54	-1.55
2030	3.36	2.08	0.64	3.18	0.04
2032	3.90	2.42	1.30	3.00	1.04
2035	3.90	2.42	1.86	3.00	1.40

6. Reverse check: this is the finding

Holding all other assumptions at base case, what does USD 158.83 require from intismeran beyond melanoma?

Probability of success assumed	Required worldwide peak sales
35%	USD 144B
50%	USD 101B
65%	USD 78B
80%	USD 63B

For scale: Keytruda peaks around USD 30B and Humira peaked around USD 21B. At an 80% probability of success — implying near-certainty across lung, bladder, head-and-neck and colorectal cancer — the current price still requires intismeran to be roughly twice the size of Keytruda. At a more realistic 50%, it requires more than three times Keytruda.

The sensitivity grid confirms this is not an artifact of one input. Probability-weighted fair value per share:

Expansion peak / PoS	35%	50%	65%
USD 8B	35	35	36
USD 15B	36	39	42
USD 25B	41	46	52
USD 40B	49	57	66

Even a USD 40B expansion franchise at a 65% probability of success produces only USD 66 per share.

7. What the melanoma win does not fix

Moderna owns half of intismeran, not all of it. Under the 2016 collaboration as amended, and following Merck's October 2022 option exercise for USD 250m, costs and profits are shared equally on a worldwide basis. Moderna runs manufacturing and process development while Merck leads clinical development. Every dollar of franchise value is halved before it reaches this equity.

Individualized neoantigen therapy economics are not vaccine economics. Each dose is bespoke: tumour sequencing, neoantigen selection, a GMP batch of one, cold chain, and weeks of turnaround. Gross margins should resemble CAR-T at 50-70%, not the 90% of a small molecule. Moderna is the party carrying that manufacturing cost inside the collaboration.

The base business is impaired, not merely cyclical. Revenue fell 40% in 2025. FY26 gross margin on guidance is 19%. A comparison with BioNTech, which owns the same modality thesis, is instructive:

Metric	MRNA	BNTX
Net cash	USD 5.35B	USD 18.84B
Cash as % of market cap	8%	66%
Enterprise value	USD 57.7B	USD 9.8B
EV / FY26E sales	26.9x	4.8x
Lead oncology asset	Ph3 win, 50% owned	Ph2, 50% owned

Moderna holds roughly one-quarter of BioNTech's cash and carries roughly six times the enterprise value. It is the leveraged expression of the same modality thesis.

8. What went right, and where the gap to consensus sits

The bear case should not obscure genuine progress:

• mFlusiva (mRNA-1010) is approved for adults aged 50 and over, the first mRNA seasonal influenza vaccine licensed in the United States. The advisory committee voted 9-0 on both the 50-64 and 65-plus questions in June 2026, completing a turnaround from February's refusal-to-file. Relative vaccine efficacy was 26.6% against a standard-dose comparator.
• INTerpath-001 is a genuine first — the first positive Phase 3 readout for any individualized neoantigen therapy and for any mRNA-based cancer therapy.
• Cost discipline is real: approximately USD 2.2B of annual operating expense removed in 2025, with guidance cut again in Q2 2026.

The entire delta to consensus is the assumed size of the addressable INT market. This model applies four discounts that the optimistic case tends to skip:

1. The 50% Merck split halves everything.
2. N-of-1 manufacturing margins of 50-55%, not 70% or above.
3. The corporate cost base is not free. Approximately USD 3.0B of steady-state R&D and SG&A against a USD 2.4B gross profit stream. Moderna does not reach positive free cash flow until 2030 in the base case.
4. Melanoma is the easy tumour: high mutational burden and checkpoint-responsive. The 35% base-case probability of success for expansion reflects that the hard indications remain unproven. Moderna's own chief development officer framed the open question as whether intismeran works where checkpoint inhibitors have failed.

If the adjuvant INT market is genuinely USD 60B or more worldwide and Moderna sustains margins above 60%, the consensus numbers follow. Phase 3 data in a single tumour type does not yet support that.

9. Levels and triggers

Zone	Price (USD)	Basis
Current	158.83	Requires above USD 100B INT expansion peak at 50% PoS
Consensus price target	99.82	23 analysts
Bull DCF	89	USD 22B expansion peak, 55% PoS
Pre-readout close (18 Aug)	62.96	The market's own prior
PWFV	35	30 / 50 / 20 weighted
Base NAV	25	Option floor binding
Bear / wind-down floor	17	Net cash less wind-down plus INT stake sale

Triggers set in advance

• Full INTerpath-001 data at the next congress. No hazard ratio has been published. The Phase 2b hazard ratio was 0.51 on approximately 157 patients with a confidence interval of 0.294 to 0.887. A Phase 3 hazard ratio materially above 0.70 across 1,137 patients is a downgrade to the entire franchise, and the width of that earlier interval makes it plausible.
• First expansion readout in a checkpoint-refractory tumour. This carries the whole bull thesis. A miss takes expansion probability of success toward 15%.
• mFlusiva ACIP recommendation. Approval without a CDC recommendation caps commercial uptake through the zero-copay pathway. Currently unresolved.
• Policy overhang. HHS terminated 22 BARDA mRNA vaccine investments worth nearly USD 500m, and a USD 766m Moderna pandemic influenza contract was cancelled. The current ACIP composition is openly sceptical of the platform. This is a live and uninsurable risk to the vaccine half of the business.
• Equity issuance. At USD 159 with a loss-making base business, an at-the-market programme or secondary offering is the rational move for management and dilutive for holders. Model it explicitly if it appears.

10. Where this could be wrong

1. The INT market could be far larger than modelled. This is the single input that decides the answer. The base case assumes a USD 8B worldwide expansion peak; consensus implies multiples of that. If adjuvant INT becomes standard of care across five major tumour types, USD 40B or more is not absurd and fair value moves to USD 66.
2. Steady-state operating expense may be too high. The base case assumes USD 3.0B. Moderna has beaten its cost targets twice. At USD 2.2B steady state the base case improves by roughly USD 6-8 per share.
3. The option floor is a judgment, not a calculation. The 50% INT stake is valued at USD 3-9B in a wind-down. Merck would plausibly pay considerably more for full control following a Phase 3 win. An outright buyout of Moderna's half is a genuine upside path not modelled as a discrete scenario.
4. Momentum is not valuation. The stock moved from USD 62.96 to USD 174.38 in a single session. Being 78% below spot on a name with this much narrative energy means being either early or wrong, and there is no way to distinguish those in real time. This is a valuation view, not a timing view, and shorting it is a separate question with a different answer.
5. Risk-free rate is unverified, and share count is derived from the quarterly loss divided by loss per share rather than taken from a filing cover page.

---

Sources: Moderna Q2 2026 results release and earnings call (31 July 2026); Moderna Q4 and FY2025 results release (13 February 2026); Moderna Q1 2026 Form 8-K exhibit; Moderna FY2023 Form 10-K (Merck INT agreement terms); Merck and Moderna INTerpath-001 announcement (19 August 2026); Merck option exercise release (12 October 2022); FDA VRBPAC and mFlusiva approval reporting; HHS and BARDA contract termination reporting; Alpha Vantage GLOBAL_QUOTE (25-26 August 2026).

Disclaimer: This note is independent research for informational purposes only. It is not investment advice and is not a recommendation to buy or sell any security. This valuation differs materially from published sell-side consensus, and the assumptions driving that difference are stated explicitly so readers can form their own view. Valuation outputs depend on assumptions that may be wrong. Readers should conduct their own due diligence and consult a licensed adviser. No position disclosed.